Form 4: BioCardia CEO Peter Altman Increases Stake in BCDA

BioCardia, Inc. President and CEO Peter Altman purchased 5,100 shares of common stock at a weighted average price of $1.02.

Summary

• Peter Altman, President and CEO of BioCardia, Inc., acquired 5,100 shares of common stock.
• The transaction occurred on May 15, 2026.
• The shares were purchased at a weighted average price of $1.02 per share, with individual trades ranging from $1.01 to $1.03.
• Following this transaction, Mr. Altman's total beneficial ownership in the company increased to 285,866 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the CEO's commitment of personal capital suggests confidence in the company's future prospects.

Positives

• Insider confidence is demonstrated by the CEO's decision to increase his personal equity stake in the company.
• The purchase was made at market prices, signaling alignment between management and shareholder interests.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal of management's belief in the company's clinical pipeline and long-term valuation, particularly when shares are trading at lower price points.

Comparison to Industry Standards

• Insider buying is generally considered a bullish indicator compared to the broader market, where executive selling is more common for liquidity purposes.

Stakeholder Impact

• Shareholders may interpret this as a sign of stability and confidence from the company's leadership.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Recommendation

While insider buying is a positive signal, a single purchase of 5,100 shares is relatively small in the context of total outstanding shares and does not fundamentally alter the investment thesis for the company.

Keywords

BioCardia, BCDA, Insider Trading, Peter Altman, Form 4, Biotech